EKF Diagnostics Holdings (GB:EKF) has released an update.
EKF Diagnostics Holdings PLC reports a robust first half of 2024, with significant improvements in gross margins, earnings growth, and cash flow, in line with projections. By concentrating on high-margin products and core operations, the company has seen a revenue of £24.5m from ongoing operations, a gross profit increase to £12.1m, and a notable rise in adjusted EBITDA by 22.7% to £5.4m. These financial gains reflect the successful refocusing on their Point-of-Care and Life Sciences divisions, with the company expecting continued performance improvement in the latter half of the year.
For further insights into GB:EKF stock, check out TipRanks’ Stock Analysis page.
